Biotech

All Articles

OS Therapies refiles $6M IPO to finance HER2 drug, preclinical ADCs

.Operating system Therapies will certainly list on the NYSE American supply exchange this morning vi...

ALX's fizzling CD47 response cost delivers sell spiraling down

.ALX Oncology's stage 2 stomach cancer cells action rate has actually compromised. After finding its...

Ionis centers eye illness coming from targets of Roche-partnered possibility after information disappoint

.An Additional of Ionis Pharmaceuticals' crucial midphase readouts has fallen short of requirements,...

Biogen's CEO claimed no risky handle 2023. He prepares to become bold

.While Biogen's pharma peers are looking for late-stage resources along with little danger, chief ex...

Instil refills pipe in $2B biobucks manage ImmunOnco

.Instil Bio has actually been actually a biotech looking for a pipe after it junked its lead assets ...

Biogen walks away from Denali Alzheimer's collab

.Biogen has actually returned civil liberties to an early Alzheimer's ailment course to Denali Thera...

Takeda faucets new head of US oncology service-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of considerable management hirings, firings...

Vertex, beaten by AATD once again, loses 2 possessions on discard stack

.Tip's try to alleviate an unusual hereditary ailment has reached an additional drawback. The biotec...

Vir gains 3 T-cell engagers coming from Sanofi, gives up 25% of workers

.Vir Biotechnology's second-quarter earnings document had not been short of huge information. The bu...

Galapagos stops CAR-T cell treatment litigation over Parkinsonism scenario

.Galapagos has paused registration in a test of a BCMA-directed CAR-T cell treatment, pushing the br...